Live feed07:00:00·824dPRReleasevia QuantisnowGracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple MyelomaByQuantisnow·Wall Street's wire, on your screen.GRCL· Gracell Biotechnologies Inc.Health Care
